Moderna has reported preliminary clinical ... that it is too early to consider widespread use of a second COVID-19 vaccine booster dose in the EU. EnteroBiotix has reported phase 2a proof-of ...

Researchers have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against potential ...

COVID-19 spring booster can cut your risk of hospitalization by over 40%! If you're 75+, immunocompromised, or in a care home, you’re eligible. Stay protected—book your jab now.

Starting from April 8, people aged 65 and older, indigenous people aged 55 to 64, children younger than six months old and ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

“The companies told the PTAB in the petitions that Moderna’s patents include ‘unimaginably broad claims directed to a basic idea.’” Patent Trial and Appeal Board (PTAB) docket entries ...

The stock has a 52-week high of over $170 while Moderna entered 2020 trading below $20, making insiders more likely to have large gains. The biotech surged during Covid to top $400, but Moderna ...

March 5 - Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab won a round in their legal battle with Moderna (MRNA.O), opens new tab over COVID-19 vaccine patents on Wednesday ...